Upregulation of long non-coding RNA TUG1 correlates with poor prognosis and disease status in osteosarcoma

Abstract

The pathogenesis of osteosarcoma involves complex genetic and epigenetic factors. This study was to explore the impact and clinical relevance of long non-coding RNA (lncRNA), Taurine up-regulated gene 1 (TUG1) on patients with osteosarcoma. Seventy-six osteosarcoma tissues and matched adjacent normal tissues were included for analysis. The plasma samples were obtained from 29 patients with osteosarcoma at pre-operation and post-operation, 42 at newly diagnosed, 18 who experienced disease progression or relapse, 45 post-treatment, 36 patients with benign bone tumor, and 20 healthy donors. Quantitative real-time reverse transcript polymerase chain reactions were used to assess the correlation of the expression levels of TUG1 with clinical parameters of osteosarcoma patients. TUG1 was significantly overexpressed in the osteosarcoma tissues compared with matched adjacent normal tissues (P < 0.01) and was closely correlated with tumor size, post-operative chemotherapy, and Enneking surgical stage. Upregulation of TUG1 strongly correlated with poor prognosis and was an independent prognostic indicator for overall survival (HR = 2.78, 95% CI = 1.29-6.00, P = 0.009) and progression-free survival (HR = 1.81, 95% CI = 1.01-3.54, P = 0.037). Our constructed nomogram containing TUG1 had more predictive accuracy than that without TUG1 (c-index 0.807 versus 0.776, respectively). In addition, for plasma samples, TUG1 expression levels were obviously decreased in post-operative patients (mean ΔCT -4.98 ± 0.22) compared with pre-operation patients (mean ΔCT -6.09 ± 0.74), and the changes of TUG1 expression levels were significantly associated with disease status. Receiver operating characteristic (ROC) curve analysis demonstrated that TUG1 could distinguish patients with osteosarcoma from healthy individuals compared with alkaline phosphatase (ALP) (the area under curve 0.849 versus 0.544). TUG1 was overexpressed in patients with osteosarcoma and strongly correlated with disease status. In addition, TUG1 may serve as a molecular indicator in maintaining surveillance and forecasting prognosis.

High TUG1 expression is associated with chemotherapy resistance and poor prognosis in esophageal squamous cell carcinoma

“…TUG1 was significantly upregulated in ESCC tissues compared with adjacent non-cancerous tissues. This result agrees with the findings of previous studies [14,15,25]. Furthermore, patients with high TUG1 expression showed worse OS, which may explain the high prevalence of chemotherapy resistance in cases with TUG1 overexpression.…”

“…The normal expression of TUG1 is thus speculated to exert an inhibitory effect on some apoptosis-related genes; that is to say, TUG1 may exert an anti-apoptotic effect similar to that of survivin [12]. Ma et al [15] recently reported that TUG1 expression was upregulated in osteosarcoma, and its high expression leads to poor prognosis and short survival time. Han et al [14] reported upregulation of TUG1 in bladder urothelial carcinoma affecting cell proliferation and apoptosis.…”

“…It is called TUG1 because its expression could be upregulated with addition of taurine [12]. TUG1 was recently confirmed to be upregulated in colorectal cancer [10], hepatocellular carcinoma [13], urothelial carcinoma of the bladder [14], and osteosarcoma [15] and thus facilitates the proliferation of tumor cells. By contrast, TUG1 expression has been reported to be downregulated in non-small cell lung cancer (NSCLC) and glioma [16,17], and thus, it may function as a tumor suppressor in some types of cancer.…”

Long noncoding RNA <em>SPRY4-IT1</em> promotes malignant development of colorectal cancer by targeting epithelial&ndash;mesenchymal transition

“…Total RNA was extracted from tissues or serum samples by Trizol reagent (Thermo Fisher Scientific) and Trizol LS reagent (Thermo Fisher Scientific) as described in our previous study 16. cDNA was synthesized using the PrimeScript RT reagent Kit with gDNA Eraser (Takara, Dalian, People’s Republic of China).…”

Prognostic value of abnormally expressed long non-coding RNAs in patients with osteosarcoma: a meta-analysis

“…Of these, 129 duplicated articles were excluded; through title and abstract review, studies describing unrelated topics (n = 80) which refers to those studies that were not research articles or those studies unrelated to osteosarcoma, lncRNA , or patient prognosis were removed; after reading the remaining 54 full-text articles, studies lacking relevant data (n = 32), studies presented in language other than English (n = 1), fulltext unavailable studies (n = 1), and the studies of which included patients were reported in previous studies (n = 1) were excluded. Eventually, 19 studies (containing 1298 patients) met the inclusion criteria and were evaluated in this analysis [18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36]. The screening process and results was shown in Figure 1.…”